Synaffix BV

Formed in 2010, Synaffix is a Netherlands-based biotechnology company exclusively focused on continued advancement of a best-in-class antibody-drug conjugate (ADC) technology platform. As a leading innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, the vision of Synaffix is to become the preferred partner in the development of these complex biological therapeutics and realize its ambition - connect to cure.

http://www.synaffix.com/

Team Member
more about
Hakan Goker
Latest News Entry
2017/02/20
New Data Demonstrate Significant Expansion of Therapeutic Index vs Cysteine-Engineered ADCs

AMSTERDAM, NETHERLANDS – February 20, 2017 – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology, today announced a new set of head-to-head data, that demonstrates the potential of its technology to significantly expand the therapeutic index vs cysteine-engineered ADCs.

all portfolio news